TMCnet News
Financialbussinessnews.US: FinancialBusinessNews.US: Stock News: PETM & THRX(M2 PressWIRE Via Acquire Media NewsEdge) RDATE:20112008 PetSmart, Inc. (NASDAQ: PETM); Theravance, Inc. (NASDAQ: THRX) FinancialBusinessNews is part of Stock Profiler.US, LLC's News Division. Stock Profiler welcomes investors to chat LIVE about these stocks and more on their upgraded website with FREE Investor Tools, Live Chats, and much more! Sign up now at www.stockprofiler.us. Companies who want to broadcast their message are encouraged to contact Stock Profiler.US, LLC at (603) 424-4420. ------------------------------------------- PetSmart, Inc. (NASDAQ: PETM) closed at $13.32 Wednesday, trading 3,793,400 shares. Company News- November 19, 2008: PetSmart Reports Results for the Third Quarter 2008 Yesterday PetSmart, Inc. (NASDAQ: PETM) reported net income of $35.8 million, or $0.28 per share, for the third quarter of 2008. That compares with net income of $29.5 million, or $0.23 per share, for the third quarter of 2007. To read the full news release, go to www.stockprofiler.us, and click the Headline link after entering the ticker symbol. About PetSmart PetSmart, Inc. is the largest specialty pet retailer of services and solutions for the lifetime needs of pets. The company operates more than 1,107 pet stores in the United States and Canada, 132 in-store PetSmart PetsHotels cat and dog boarding facilities, and is a leading online provider of pet supplies and pet care information (www.petsmart.com). PetSmart provides a broad range of competitively priced pet food and pet products; and offers complete pet training, pet grooming, pet boarding, doggie day camp and pet adoption services. Since 1994, PetSmart Charities , Inc., an independent 501(c)(3) non-profit animal welfare organization, has funded more than $70 million in grants and programs benefiting animal welfare organizations and, through its in-store pet adoption programs, has helped save the lives of more than 3 million pets. ------------------------------------------- Theravance, Inc. (NASDAQ: THRX) closed at $6.85 Wednesday, trading 1,254,500 shares. Company News- November 19, 2008: Theravance Reports Favorable Outcome of FDA Advisory Committee Meeting on Telavancin for the Treatment of Complicated Skin and Skin Structure Infections Theravance, Inc. (NASDAQ: THRX) announced yesterday that telavancin received a favorable recommendation from the Anti-Infective Drugs Advisory Committee (AIDAC) of the U.S. Food and Drug Administration (FDA) for the proposed indication to treat complicated skin and skin structure infections (cSSSIs) caused by Gram-positive bacteria, including resistant pathogens such as methicillin-resistant Staphylococcus aureus (MRSA). The Committee voted 21 to 5 that the data presented demonstrate the safety and effectiveness of telavancin for treatment of cSSSIs. The Committee also voted 18 to 5 (with 3 abstentions) that there are specific clinical situations in which the benefits of telavancin use in pregnant women with cSSSI would outweigh the risks, and 25 to 1 that a risk management strategy is needed to prevent unintended use of telavancin in pregnant women or women of child-bearing potential. Telavancin is a novel, bactericidal, once-daily injectable investigational antibiotic discovered by Theravance. To read the full news release, go to www.stockprofiler.us, and click the Headline link after entering the ticker symbol. About Telavancin Telavancin is a bactericidal, once-daily injectable investigational antibiotic with a multifunctional mechanism of action. Telavancin was discovered by Theravance in a research program dedicated to finding new antibiotics for serious infections due to Staphylococcus aureus and other Gram-positive bacteria, including MRSA. Telavancin inhibits the formation of the bacterial cell wall and disrupts bacterial cell membrane function. Theravance believes the additive mechanisms of action seen with telavancin speed bacterial killing while also reducing the risks of inducing resistance to telavancin or cross-resistance with other antibiotics. If approved, telavancin will be a new treatment option for serious Gram-positive cSSSIs. In addition, two Phase 3 studies of telavancin have been completed for the treatment of hospital-acquired pneumonia bacterial infections. About ATLAS 1 and ATLAS 2 Clinical Studies The telavancin NDA is based on data from two large, multinational, double-blind, randomized Phase 3 clinical studies designed to compare the efficacy and safety of telavancin (10 mg/kg IV once daily) versus vancomycin (1 gm IV q 12hr) in the treatment of cSSSIs caused by Gram-positive bacteria. In both of these studies (ATLAS 1 and ATLAS 2), infections with MRSA, telavancin achieved its primary endpoint of non-inferiority relative to the standard of care, vancomycin. The safety profile of telavancin in these studies was compatible with treatment of patients with serious infections. About the Telavancin Collaboration In November 2005, Theravance entered into a collaboration arrangement with Astellas Pharma Inc. for the development and commercialization of telavancin worldwide except Japan. In July 2006, Theravance and Astellas expanded the collaboration to include Japan. Under the terms of the collaboration, Theravance will lead the development of and U.S. regulatory activities for telavancin for the treatment of cSSSIs and hospital-acquired pneumonia, and will collaborate substantially with Astellas in marketing in the United States for the first three years. Astellas will lead all other development, regulatory, manufacturing, sales and marketing activities. About Theravance Theravance is a biopharmaceutical company with a pipeline of internally discovered product candidates. Theravance is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections and gastrointestinal motility dysfunction. The company's key programs include: telavancin for the treatment of serious Gram-positive bacterial infections with Astellas Pharma Inc., the Horizon program and Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA) program with GlaxoSmithKline plc, and the Gastrointestinal Motility Dysfunction program. By leveraging its proprietary insight of multivalency toward drug discovery focused primarily on validated targets, Theravance is pursuing a next generation strategy designed to discover superior medicines in areas of significant unmet medical need. For more information, please visit the company's web site at www.theravance.com. ------------------------------------------- The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. FinancialBusinessNews.US is a division of Stock Profiler.US, LLC's News Division, which includes but is not limited to www.StockProfiler.us, www.AssociatesFortune.com, www.FinancialBusinessNews.us, www.FastMoneyTalk.com, www.MarketTelegraph.com, www.TheWallStreetLeader.com and www.DayTradersDigest.com. Stock Profiler.US, LLC has not been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities mentioned herein. To view full disclaimers and terms of use, go to www.stockprofiler.us. KEYWORD: Small Cap Investments, Investor Relations, I/R Services, Investment Tools, Stock Profiles, Stock Market Quotes News, Media Coverage, United States, North America, Massachusetts INDUSTRY KEYWORD: Energy, Alternative Energy, Coal, Oil/Gas, Utilities, Natural Resources, Other Natural Resources, Professional Services, Consulting CONTACT: Financialbussinessnews.US Tel: +1 603 424 4420 e-mail: [email protected] WWW: http://www.financialbusinessnews.com ((M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [email protected])). Copyright ? 2008 M2 Communications Ltd. |